Tahoe-100M: A Giga-Scale Single-Cell Perturbation Atlas for Context-Dependent Gene Function and Cellular Modeling

Cite

Zhang, J., Ubas, A.A., de Borja, R., Svensson, V., Thomas, N., Thakar, N., Lai, I., Winters, A., Khan, U., Jones, M.G. and Thompson, J.D., 2025. Tahoe-100m: A giga-scale single-cell perturbation atlas for context-dependent gene function and cellular modeling. bioRxiv, pp.2025-02. https://doi.org/10.1101/2025.02.20.639398

Abstract

Building predictive models of the cell requires systematically mapping how perturbations reshape each cell’s state, function, and behavior. Here, we present Tahoe-100M, a giga-scale single-cell atlas of 100 million transcriptomic profiles measuring how each of 1,100 small-molecule perturbations impact cells across 50 cancer cell lines. Our high-throughput Mosaic platform, composed of a highly diverse and optimally balanced “cell village”, reduces batch effects and enables parallel profiling of thousands of conditions at single-cell resolution at an unprecedented scale. As the largest single-cell dataset to date, Tahoe-100M enables artificial-intelligence (AI)-driven models to learn context-dependent functions, capturing fundamental principles of gene regulation and network dynamics. Although we leverage cancer models and pharmacological compounds to create this resource, Tahoe-100M is fundamentally designed as a broadly applicable perturbation atlas and supports deeper insights into cell biology across multiple tissues and contexts. By publicly releasing this atlas, we aim to accelerate the creation and development of robust AI frameworks for systems biology, ultimately improving our ability to predict and manipulate cellular behaviors across a wide range of applications.

Summary

Drug treatments

1. Talc # 217,493 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Talc used in pharma and cosmetics; safety under review for some uses.	Explore
2. Bortezomib # 127,948 cells Human approved Clinical trials Targets: PSMB5 Mechanism of action: Proteasome inhibitor (inhibitor/antagonist) Description: Approved for multiple myeloma and mantle cell lymphoma.	Explore
3. Ixazomib # 175,001 cells Human approved Clinical trials Targets: PSMB5 Mechanism of action: Proteasome inhibitor (inhibitor/antagonist) Description: Approved for multiple myeloma treatment.	Explore
4. Ixazomib citrate # 187,826 cells Human approved Clinical trials Targets: PSMB1 PSMB2 PSMB5 Mechanism of action: Proteasome inhibitor (inhibitor/antagonist) Description: Approved for multiple myeloma treatment as part of a combination therapy.	Explore
5. Lactate (calcium) # 230,188 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in medical settings, but not specifically approved as a standalone drug.	Explore
6. Bisoprolol (hemifumarate) # 153,499 cells Human approved Clinical trials Targets: ADRB1 Mechanism of action: Adrenoceptor agonist (inhibitor/antagonist) Description: Approved for hypertension, heart failure, and angina.	Explore
7. Fumaric acid # 549,353 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in psoriasis treatment as part of fumaric acid esters.	Explore
8. Hydroxyurea # 137,690 cells Human approved Clinical trials Targets: RRM2 RRM1 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for sickle cell anemia and certain cancers.	Explore
9. L-Eflornithine (monohydrochloride) # 235,714 cells Human approved Clinical trials Targets: ODC1 Mechanism of action: unclear Description: Used to treat sleeping sickness. Approved for human use.	Explore
10. Cysteamine (hydrochloride) # 273,418 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: FDA-approved for cystinosis treatment.	Explore
11. Darinaparsin # 234,376 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in clinical trials for certain cancers only.	Explore
12. Entecavir (monohydrate) # 329,142 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treating hepatitis B infection.	Explore
13. Allantoin # 261,587 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Allantoin is approved as a skin protectant by the FDA.	Explore
14. 5-Fluorouracil # 249,048 cells Human approved Clinical trials Targets: TYMS Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Widely used chemotherapy drug. Approved for cancer treatment.	Explore
15. L-Thyroxine (sodium salt pentahydrate) # 190,420 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for hypothyroidism, a form of standard thyroid hormone replacement therapy.	Explore
16. Gallic acid # 330,734 cells Human approved Clinical trials Targets: None Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used in supplements, studied for antioxidant properties.	Explore
17. Gallic acid (hydrate) # 243,685 cells Human approved Clinical trials Targets: None Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Evaluated in trials but not approved as a standalone drug.	Explore
18. ERK5-IN-2 # 184,993 cells Human approved Clinical trials Targets: MAPK7 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Not found in clinicaltrials.gov database as of the latest available data.	Explore
19. Vilanterol # 206,941 cells Human approved Clinical trials Targets: ADRB2 Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Combined with fluticasone furoate for asthma and COPD treatment.	Explore
20. Niclosamide (olamine) # 243,762 cells Human approved Clinical trials Targets: STAT3 Mechanism of action: unclear Description: Approved for parasitic infections, investigated for other uses.	Explore
21. Norepinephrine (hydrochloride) # 277,865 cells Human approved Clinical trials Targets: ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Approved for human use as a medication to treat low blood pressure.	Explore
22. Triclosan # 284,345 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Banned in soaps; used in some consumer products and healthcare settings.	Explore
23. Mitoxantrone (dihydrochloride) # 193,028 cells Human approved Clinical trials Targets: TOP2A TOP2B PRKCA Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for cancer and multiple sclerosis treatment.	Explore
24. Pentamidine (isethionate) # 307,259 cells Human approved Clinical trials Targets: PRLR Mechanism of action: unclear Description: Used to treat Pneumocystis pneumonia and African trypanosomiasis.	Explore
25. Folic acid # 322,830 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Widely used as a dietary supplement and in fortified foods.	Explore
26. Balsalazide (sodium hydrate) # 313,467 cells Human approved Clinical trials Targets: IL6 STAT3 Mechanism of action: JAK/STAT inhibitor (unclear) Description: Used for ulcerative colitis treatment in humans.	Explore
27. Resveratrol # 254,402 cells Human approved Clinical trials Targets: SIRT1 Mechanism of action: unclear Description: Studies showed promising results, but no approval for therapeutic use.	Explore
28. PF-06260933 # 202,652 cells Human approved Clinical trials Targets: MAP4K4 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated for treating pain; not approved for human use.	Explore
29. Daidzin # 493,522 cells Human approved Clinical trials Targets: ALDH2 Mechanism of action: unclear Description: investigated for alcoholism; not approved for treatment	Explore
30. Pemetrexed # 139,883 cells Human approved Clinical trials Targets: TYMS DHFR GART Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Chemotherapy drug for mesothelioma and non-small cell lung cancer.	Explore
31. Econazole # 280,500 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Antifungal approved for dermatological use.	Explore
32. XRK3F2 # 157,778 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: No results found on clinicaltrials.gov	Explore
33. Arbutin # 184,795 cells Human approved Clinical trials Targets: MYC KLF4 Mechanism of action: unclear Description: Used in cosmetics, trials for skin-lightening, not approved as a drug.	Explore
34. Tucidinostat # 275,726 cells Human approved Clinical trials Targets: HDAC1 HDAC2 HDAC3 HDAC10 HDAC8 HDAC11 Mechanism of action: HDAC inhibitor (inhibitor/antagonist) Description: Approved for use in China for certain cancers.	Explore
35. Pexidartinib (hydrochloride) # 245,688 cells Human approved Clinical trials Targets: CSF1R KIT FLT3 Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for tenosynovial giant cell tumor in 2019.	Explore
36. Sodium Salicylate # 274,234 cells Human approved Clinical trials Targets: PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used in studies, NSAID-related research, not approved for standard human therapy.	Explore
37. Salicylic acid # 277,326 cells Human approved Clinical trials Targets: None Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used topically for acne and in aspirin synthesis.	Explore
38. Ataluren # 344,302 cells Human approved Clinical trials Targets: CFTR Mechanism of action: unclear Description: For Duchenne muscular dystrophy with specific genetic mutation.	Explore
39. 4EGI-1 # 204,072 cells Human approved Clinical trials Targets: EIF4E Mechanism of action: Protein synthesis inhibitor (inhibitor/antagonist) Description: No clinical trials found for 4EGI-1 on clinicaltrials.gov.	Explore
40. Clotrimazole # 241,960 cells Human approved Clinical trials Targets: CYP2A6 CYP51A1 Mechanism of action: unclear Description: Antifungal used in topical and oral preparations.	Explore
41. Phenytoin (sodium) # 167,137 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Commonly used as an anti-seizure medication.	Explore
42. SBI-0640756 # 92,889 cells Human approved Clinical trials Targets: None Mechanism of action: Protein synthesis inhibitor (inhibitor/antagonist) Description: No record found on clinicaltrials.gov.	Explore
43. Oxaprozin # 181,674 cells Human approved Clinical trials Targets: PTGS1 PTGS2 NFKB1 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Approved NSAID for arthritis treatment.	Explore
44. Baicalin # 327,146 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in traditional medicine, researched for various pharmacological effects.	Explore
45. Belinostat # 200,872 cells Human approved Clinical trials Targets: HDAC6 Mechanism of action: HDAC inhibitor (inhibitor/antagonist) Description: Approved for relapsed/refractory peripheral T-cell lymphoma.	Explore
46. Carbamazepine # 178,753 cells Human approved Clinical trials Targets: None Mechanism of action: HDAC inhibitor (inhibitor/antagonist) Description: Used for epilepsy and neuropathic pain.	Explore
47. HI-TOPK-032 # 137,177 cells Human approved Clinical trials Targets: PBK Mechanism of action: unclear Description: No results found on clinicaltrials.gov.	Explore
48. 8-Hydroxyquinoline # 290,019 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in some clinical trial formulations, not approved as standalone drug.	Explore
49. Riluzole hydrochloride # 304,805 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in ALS treatment.	Explore
50. Minodronic acid # 254,013 cells Human approved Clinical trials Targets: P2RX2 P2RX3 Mechanism of action: unclear Description: Investigated for osteoporosis; not approved in major markets.	Explore
51. GSK1059615 # 181,871 cells Human approved Clinical trials Targets: PIK3CA PIK3CB PIK3CD PIK3CG MTOR Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: Investigated in trials, not approved for human use.	Explore
52. Gemcitabine # 371,258 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for cancer treatment like pancreatic and non-small cell lung cancer.	Explore
53. Cytarabine # 551,715 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in chemotherapy for leukemia and other cancers.	Explore
54. Cytarabine (hydrochloride) # 204,969 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in chemotherapy for leukemia and lymphoma.	Explore
55. Uridine # 412,491 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Studied in trials; not approved as standalone drug, essential body metabolite.	Explore
56. Selinexor # 256,484 cells Human approved Clinical trials Targets: XPO1 Mechanism of action: unclear Description: Approved for certain cancer treatments.	Explore
57. Furosemide # 239,590 cells Human approved Clinical trials Targets: SLC12A1 SLC12A2 Mechanism of action: unclear Description: Widely used diuretic, approved for various conditions like hypertension and edema.	Explore
58. Adenosine # 277,315 cells Human approved Clinical trials Targets: ADORA1 ADORA2A ADORA2B ADORA3 Mechanism of action: unclear Description: Used for certain arrhythmias; approved as a drug.	Explore
59. 5-Azacytidine # 196,913 cells Human approved Clinical trials Targets: DNMT1 Mechanism of action: DNA methyltransferase inhibitor (inhibitor/antagonist) Description: Approved for use in specific cancers, such as myelodysplastic syndromes.	Explore
60. Clofarabine # 131,378 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for leukemia treatment in pediatric patients.	Explore
61. Adenine # 308,686 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Commonly found in supplements; not a drug approved by itself.	Explore
62. Allopurinol # 345,448 cells Human approved Clinical trials Targets: XDH Mechanism of action: unclear Description: Approved for gout treatment, reduces uric acid levels.	Explore
63. Trifluridine # 255,273 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used to treat viral infections and in cancer therapy (with tipiracil).	Explore
64. Brivudine # 219,894 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved in Europe, not widely used in the US.	Explore
65. Idoxuridine # 251,838 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (unclear) Description: Used as topical antiviral in eye infections. Approved for human use.	Explore
66. Decitabine # 155,733 cells Human approved Clinical trials Targets: DNMT1 DNMT3A DNMT3B Mechanism of action: DNA methyltransferase inhibitor (inhibitor/antagonist) Description: Approved for treatment of myelodysplastic syndromes and acute myeloid leukemia.	Explore
67. Lenalidomide (hemihydrate) # 206,283 cells Human approved Clinical trials Targets: CRBN IKZF1 IKZF3 Mechanism of action: unclear Description: Approved for multiple myeloma and other conditions.	Explore
68. DT-061 # 187,622 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated for oncology, no approval yet for human use.	Explore
69. BAY1125976 # 207,735 cells Human approved Clinical trials Targets: AKT1 AKT2 AKT3 Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: Cancer treatment trials but not approved for human use.	Explore
70. Larotrectinib # 219,702 cells Human approved Clinical trials Targets: NTRK1 NTRK2 NTRK3 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved specifically as a cancer treatment for tumors with NTRK gene fusions.	Explore
71. Larotrectinib sulfate # 239,747 cells Human approved Clinical trials Targets: NTRK1 NTRK2 NTRK3 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Larotrectinib sulfate is approved to treat TRK fusion-positive cancers.	Explore
72. olaparib # 245,440 cells Human approved Clinical trials Targets: PARP1 PARP2 Mechanism of action: DNA synthesis/repair inhibitor (unclear) Description: Approved for BRCA-mutated cancers.	Explore
73. Filgotinib # 315,818 cells Human approved Clinical trials Targets: JAK1 JAK2 TYK2 JAK3 Mechanism of action: JAK/STAT inhibitor (inhibitor/antagonist) Description: Approved in Japan and EU for rheumatoid arthritis.	Explore
74. ULK-101 # 122,563 cells Human approved Clinical trials Targets: ULK1 ULK2 Mechanism of action: unclear Description: No clinical trial data found on clinicaltrials.gov.	Explore
75. Oxaliplatin # 252,800 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for use in chemotherapy treatments.	Explore
76. Cilostazol # 228,611 cells Human approved Clinical trials Targets: PDE3A Mechanism of action: unclear Description: Used to treat intermittent claudication associated with peripheral artery disease.	Explore
77. LY2090314 # 214,326 cells Human approved Clinical trials Targets: GSK3B GSK3A Mechanism of action: GSK3 inhibitor (inhibitor/antagonist) Description: Investigated for Alzheimer's; not approved for any condition.	Explore
78. Cobimetinib # 117,828 cells Human approved Clinical trials Targets: MAP2K1 Mechanism of action: MEK inhibitor (inhibitor/antagonist) Description: Approved for melanoma in combination with vemurafenib.	Explore
79. Asciminib # 244,095 cells Human approved Clinical trials Targets: ABL1 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for chronic myeloid leukemia (CML) treatment.	Explore
80. Capivasertib # 201,661 cells Human approved Clinical trials Targets: AKT1 AKT2 AKT3 RPS6KB1 PRKACA ROCK2 ROCK1 Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: In clinical trials for cancer. Not yet approved for human use.	Explore
81. Penfluridol # 129,693 cells Human approved Clinical trials Targets: DRD2 Mechanism of action: unclear Description: Long-acting antipsychotic drug approved for human use.	Explore
82. Lonafarnib # 227,136 cells Human approved Clinical trials Targets: HRAS KRAS NRAS Mechanism of action: RAS inhibitor (inhibitor/antagonist) Description: Approved for progeria treatment in children.	Explore
83. Pimozide # 170,989 cells Human approved Clinical trials Targets: DRD2 DRD3 Mechanism of action: unclear Description: Approved antipsychotic used mainly for Tourette's syndrome and chronic schizophrenia.	Explore
84. Clonidine (hydrochloride) # 418,629 cells Human approved Clinical trials Targets: ADRA2A ADRA2B ADRA2C Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Used for hypertension and ADHD among other conditions.	Explore
85. Brimonidine # 314,632 cells Human approved Clinical trials Targets: ADRA2A ADRA2B ADRA2C Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Used in the form of brimonidine tartrate for glaucoma treatment.	Explore
86. AT7519 # 236,825 cells Human approved Clinical trials Targets: CDK2 CDK4 CDK5 CDK6 CDK9 CDK1 CDK7 GSK3B Mechanism of action: CDK inhibitor (inhibitor/antagonist) Description: Tested in trials for cancer treatments.	Explore
87. Hydroxyfasudil # 202,753 cells Human approved Clinical trials Targets: ROCK1 ROCK2 PRKACA Mechanism of action: unclear Description: Studied for therapeutic potential; derivative of fasudil, which is approved.	Explore
88. BI-78D3 # 172,097 cells Human approved Clinical trials Targets: None Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated for Alzheimer's and inflammatory diseases, not approved for human use.	Explore
89. ETC-206 # 222,810 cells Human approved Clinical trials Targets: None Mechanism of action: Protein synthesis inhibitor (inhibitor/antagonist) Description: Investigational drug for cancer, not yet approved for human use.	Explore
90. LJI308 # 123,009 cells Human approved Clinical trials Targets: RPS6KA1 RPS6KA3 RPS6KA2 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigational compound, not approved for human use as a drug.	Explore
91. Bimiralisib # 198,680 cells Human approved Clinical trials Targets: PIK3CA PIK3CB MTOR Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: Investigational PI3K/mTOR inhibitor; not approved for human use as of 2023.	Explore
92. Bentamapimod # 178,714 cells Human approved Clinical trials Targets: MAPK8 MAPK9 MAPK10 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated for ovarian cancer; not approved for human use.	Explore
93. Lipoic acid # 327,599 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved as dietary supplement, not as a drug for specific indications.	Explore
94. Peretinoin # 179,393 cells Human approved Clinical trials Targets: RXRA RXRB RXRG Mechanism of action: Retinoic receptor agonist (unclear) Description: Studied for liver cancer, not approved for human use.	Explore
95. IQ 1 # 142,692 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigational drug; not approved for human use yet.	Explore
96. Acetohexamide # 222,883 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: First-generation sulfonylurea, used for type 2 diabetes treatment.	Explore
97. Pentoxifylline # 276,359 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used to improve blood flow in peripheral artery disease.	Explore
98. DTP3 # 267,713 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Currently being investigated in clinical trials in the UK.	Explore
99. Acetazolamide # 212,671 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used to treat glaucoma, epilepsy, and altitude sickness since 1950s.	Explore
100. Pasireotide (acetate) # 290,235 cells Human approved Clinical trials Targets: SSTR1 SSTR2 SSTR3 SSTR5 Mechanism of action: unclear Description: Approved for Cushing's disease and acromegaly.	Explore
101. Chlorhexidine (diacetate) # 411,051 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used as antiseptic and disinfectant. Approved for human use.	Explore
102. Aspirin # 244,070 cells Human approved Clinical trials Targets: PTGS1 PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used widely for pain relief and anti-inflammatory purposes.	Explore
103. Abiraterone acetate # 293,223 cells Human approved Clinical trials Targets: CYP17A1 Mechanism of action: unclear Description: Approved for prostate cancer treatment.	Explore
104. Sivelestat (sodium tetrahydrate) # 261,741 cells Human approved Clinical trials Targets: ELANE Mechanism of action: unclear Description: Approved in Japan, not approved in US/EU.	Explore
105. Atazanavir (sulfate) # 243,032 cells Human approved Clinical trials Targets: CYP3A4 Mechanism of action: unclear Description: Antiretroviral, approved for HIV treatment.	Explore
106. Terfenadine # 309,175 cells Human approved Clinical trials Targets: HRH1 Mechanism of action: unclear Description: Withdrawn due to cardiac toxicity; replaced by fexofenadine.	Explore
107. Bosentan (hydrate) # 169,254 cells Human approved Clinical trials Targets: EDNRA EDNRB Mechanism of action: unclear Description: Approved for treating pulmonary arterial hypertension.	Explore
108. Dabrafenib # 257,191 cells Human approved Clinical trials Targets: BRAF RAF1 Mechanism of action: RAF inhibitor (inhibitor/antagonist) Description: Approved for melanoma treatment.	Explore
109. Ralimetinib dimesylate # 185,934 cells Human approved Clinical trials Targets: MAPKAPK2 MAPK14 MAPK11 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated as cancer treatment; not approved for human use.	Explore
110. Saquinavir # 161,303 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved as part of antiretroviral therapy for HIV/AIDS.	Explore
111. Pentagastrin # 296,632 cells Human approved Clinical trials Targets: CCKBR Mechanism of action: unclear Description: Used mainly in diagnostic tests for gastric functions.	Explore
112. Anastrozole # 289,294 cells Human approved Clinical trials Targets: CYP19A1 Mechanism of action: unclear Description: Used to treat breast cancer in postmenopausal women.	Explore
113. Harringtonine # 239,535 cells Human approved Clinical trials Targets: None Mechanism of action: Protein synthesis inhibitor (unclear) Description: Investigated in trials mainly for cancer treatment, often used as basis for derivatives.	Explore
114. Homoharringtonine # 215,345 cells Human approved Clinical trials Targets: None Mechanism of action: Protein synthesis inhibitor (inhibitor/antagonist) Description: Used in leukemia treatment, also known as Omacetaxine.	Explore
115. Flutamide # 223,984 cells Human approved Clinical trials Targets: AR Mechanism of action: Androgen receptor antagonist (inhibitor/antagonist) Description: Used to treat prostate cancer as an antiandrogen.	Explore
116. Thymopentin # 181,165 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: In clinical trials for immune deficiency and autoimmune diseases.	Explore
117. Aliskiren # 298,341 cells Human approved Clinical trials Targets: REN Mechanism of action: unclear Description: Renin inhibitor for hypertension. Approved in the US and EU.	Explore
118. Verapamil # 212,856 cells Human approved Clinical trials Targets: CYP3A4 ABCB1 Mechanism of action: unclear Description: Used as a racemic mixture for hypertension and angina.	Explore
119. (R)-Verapamil (hydrochloride) # 296,334 cells Human approved Clinical trials Targets: ABCB1 Mechanism of action: unclear Description: Racemic verapamil is approved, but not specifically (R)-enantiomer alone.	Explore
120. Ritonavir # 233,992 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in combination HIV therapies.	Explore
121. Goserelin (acetate) # 353,193 cells Human approved Clinical trials Targets: GNRHR Mechanism of action: unclear Description: It's approved for prostate and breast cancer treatment.	Explore
122. Bestatin # 246,652 cells Human approved Clinical trials Targets: ANPEP Mechanism of action: unclear Description: Studied in trials; not approved for human therapeutic use.	Explore
123. Bestatin (hydrochloride) # 264,336 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated in clinical trials but not approved for human use.	Explore
124. Imiquimod (maleate) # 102,679 cells Human approved Clinical trials Targets: TLR7 Mechanism of action: unclear Description: Approved for skin conditions; imiquimod itself, not specifically maleate salt.	Explore
125. Imiquimod (hydrochloride) # 212,151 cells Human approved Clinical trials Targets: TLR7 Mechanism of action: unclear Description: Approved for topical treatment of skin conditions like actinic keratosis.	Explore
126. Encorafenib # 191,556 cells Human approved Clinical trials Targets: BRAF Mechanism of action: RAF inhibitor (inhibitor/antagonist) Description: Approved for use in BRAF-mutant melanoma.	Explore
127. AZD1390 # 169,171 cells Human approved Clinical trials Targets: ATM Mechanism of action: unclear Description: Investigational ATM kinase inhibitor in clinical trials, not approved for human use.	Explore
128. Sapanisertib # 240,223 cells Human approved Clinical trials Targets: MTOR Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Investigational mTOR inhibitor, not approved yet but studied for cancer treatment.	Explore
129. Torkinib # 187,330 cells Human approved Clinical trials Targets: MTOR PDGFRA PRKDC PIK3CD PIK3CG PIK3CA PIK3CB HCK SRC KDR ABL1 EPHB4 EGFR Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: In clinical trials for cancer treatment but not yet approved.	Explore
130. Belumosudil # 527,152 cells Human approved Clinical trials Targets: ROCK2 ROCK1 Mechanism of action: unclear Description: Approved for chronic graft-versus-host disease in the US.	Explore
131. Belumosudil (mesylate) # 177,141 cells Human approved Clinical trials Targets: ROCK2 ROCK1 Mechanism of action: unclear Description: Approved for chronic graft-versus-host disease.	Explore
132. Esmolol (hydrochloride) # 340,412 cells Human approved Clinical trials Targets: ADRB1 Mechanism of action: unclear Description: Used as a beta-1 blocker for acute heart issues.	Explore
133. Erdafitinib # 111,332 cells Human approved Clinical trials Targets: FGFR1 FGFR2 FGFR3 FGFR4 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for bladder cancer treatment.	Explore
134. Malotilate # 315,613 cells Human approved Clinical trials Targets: ALOX5 Mechanism of action: unclear Description: Investigated, but not approved for human use.	Explore
135. Fenofibrate # 214,174 cells Human approved Clinical trials Targets: CYP2C19 CYP2B6 CYP2C9 CYP2C8 CYP3A4 PPARA Mechanism of action: unclear Description: Fenofibrate is approved for human use in treating hypercholesterolemia.	Explore
136. MK-8353 # 182,564 cells Human approved Clinical trials Targets: MAPK3 MAPK1 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated for cancer treatment in clinical trials.	Explore
137. crizotinib # 198,772 cells Human approved Clinical trials Targets: ALK MET ROS1 Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for NSCLC treatment.	Explore
138. (S)-Crizotinib # 238,307 cells Human approved Clinical trials Targets: NUDT1 Mechanism of action: unclear Description: Racemic mixture Crizotinib is approved, not specific enantiomer.	Explore
139. Crizotinib (hydrochloride) # 257,602 cells Human approved Clinical trials Targets: ALK MET ROS1 Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for ALK-positive NSCLC treatment.	Explore
140. Aprepitant # 248,341 cells Human approved Clinical trials Targets: TACR1 Mechanism of action: unclear Description: Aprepitant is approved for preventing chemotherapy-induced nausea and vomiting.	Explore
141. Cinacalcet # 249,106 cells Human approved Clinical trials Targets: CASR Mechanism of action: unclear Description: Used to treat secondary hyperparathyroidism and parathyroid carcinoma.	Explore
142. Naproxen # 484,400 cells Human approved Clinical trials Targets: PTGS1 PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used as non-prescription NSAID in many countries.	Explore
143. Zileuton # 256,588 cells Human approved Clinical trials Targets: ALOX5 Mechanism of action: unclear Description: Approved for asthma treatment; 5-lipoxygenase inhibitor.	Explore
144. Voriconazole # 257,565 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treating invasive fungal infections.	Explore
145. Carbidopa (monohydrate) # 317,387 cells Human approved Clinical trials Targets: AHR Mechanism of action: unclear Description: Used in combination with levodopa for Parkinson's treatment.	Explore
146. Silodosin # 148,952 cells Human approved Clinical trials Targets: ADRA1A ADRA1B ADRA1D Mechanism of action: unclear Description: Approved for benign prostatic hyperplasia treatment.	Explore
147. Darolutamide # 288,307 cells Human approved Clinical trials Targets: AR Mechanism of action: Androgen receptor antagonist (inhibitor/antagonist) Description: Approved for treating non-metastatic castration-resistant prostate cancer.	Explore
148. Benproperine (phosphate) # 197,265 cells Human approved Clinical trials Targets: ARPC2 Mechanism of action: unclear Description: Studied as a cough suppressant; not widely approved.	Explore
149. Bicalutamide # 311,710 cells Human approved Clinical trials Targets: AR Mechanism of action: Androgen receptor antagonist (inhibitor/antagonist) Description: Approved as antiandrogen for prostate cancer treatment.	Explore
150. Captopril # 304,937 cells Human approved Clinical trials Targets: ACE Mechanism of action: unclear Description: First ACE inhibitor approved for hypertension and heart failure.	Explore
151. Tirabrutinib # 280,532 cells Human approved Clinical trials Targets: BTK Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: In clinical trials, not approved for human use yet.	Explore
152. Tirabrutinib (hydrochloride) # 321,299 cells Human approved Clinical trials Targets: BTK Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Not approved in US/EU; used investigationally in some regions.	Explore
153. Mifepristone # 195,886 cells Human approved Clinical trials Targets: NR3C1 PGR Mechanism of action: unclear Description: Approved for medical abortion and Cushing's syndrome treatment.	Explore
154. Fostamatinib (disodium hexahydrate) # 253,175 cells Human approved Clinical trials Targets: SYK FLT3 LYN LCK Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for treatment of chronic immune thrombocytopenia in adults.	Explore
155. Temuterkib # 171,543 cells Human approved Clinical trials Targets: None Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Temuterkib is in clinical trials for cancer treatment.	Explore
156. Tetracycline (hydrochloride) # 260,396 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved antibiotic often used as tetracycline hydrochloride.	Explore
157. Glycyrrhizic acid # 128,810 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Tested for therapeutic effects, not approved for human use.	Explore
158. Diammonium Glycyrrhizinate # 290,764 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in trials for hepatitis. Not approved for general human use.	Explore
159. venetoclax # 213,368 cells Human approved Clinical trials Targets: BCL2 Mechanism of action: unclear Description: Approved for chronic lymphocytic leukemia and other cancers.	Explore
160. Delamanid # 267,086 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for MDR-TB treatment.	Explore
161. Dexmedetomidine # 216,194 cells Human approved Clinical trials Targets: ADRA2A ADRA2B ADRA2C Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Approved as sedative and analgesic.	Explore
162. Ranolazine # 244,484 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treating chronic angina.	Explore
163. Lopinavir # 237,498 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Combined with ritonavir for HIV treatment. Approved for human use.	Explore
164. Valdecoxib # 177,772 cells Human approved Clinical trials Targets: PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Withdrawn due to safety concerns related to cardiovascular risks.	Explore
165. Cloxacillin (sodium) # 335,754 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved as a penicillinase-resistant antibiotic for human use.	Explore
166. Elagolix sodium # 231,205 cells Human approved Clinical trials Targets: GNRHR Mechanism of action: unclear Description: Approved for endometriosis pain in women.	Explore
167. palbociclib # 165,578 cells Human approved Clinical trials Targets: CDK4 CDK6 Mechanism of action: CDK inhibitor (inhibitor/antagonist) Description: Approved for human use as a cancer treatment.	Explore
168. Retinoic acid # 303,266 cells Human approved Clinical trials Targets: RARB RARG RARA PPARD Mechanism of action: Retinoic receptor agonist (activator/agonist) Description: Approved for acne and leukemia treatment.	Explore
169. PH-797804 # 156,932 cells Human approved Clinical trials Targets: MAPK14 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigated as an anti-inflammatory agent, not approved for human use.	Explore
170. Ponatinib # 321,174 cells Human approved Clinical trials Targets: ABL1 PDGFRA KDR FGFR1 SRC KIT Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for treatment of certain types of leukemia.	Explore
171. Radotinib # 228,358 cells Human approved Clinical trials Targets: ABL1 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Tested for chronic myeloid leukemia, not approved in major markets.	Explore
172. NVP-BHG712 # 156,193 cells Human approved Clinical trials Targets: EPHB4 Mechanism of action: unclear Description: Investigated as angiogenesis inhibitor; not approved for human use.	Explore
173. Canagliflozin # 157,861 cells Human approved Clinical trials Targets: SLC5A2 Mechanism of action: Glucose transporter inhibitor (inhibitor/antagonist) Description: Approved for type 2 diabetes treatment.	Explore
174. MK-3903 # 128,217 cells Human approved Clinical trials Targets: PRKAA1 Mechanism of action: unclear Description: Investigated for NASH, not yet approved for human use.	Explore
175. EX229 # 157,352 cells Human approved Clinical trials Targets: PRKAA1 Mechanism of action: unclear Description: No clinical trial information found on clinicaltrials.gov.	Explore
176. Flumatinib (mesylate) # 512,601 cells Human approved Clinical trials Targets: ABL1 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Used in trials for chronic myeloid leukemia.	Explore
177. Tucatinib # 241,730 cells Human approved Clinical trials Targets: ERBB2 Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for human use in advanced HER2-positive breast cancer.	Explore
178. Trimetrexate # 249,091 cells Human approved Clinical trials Targets: DHFR Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used with leucovorin for treating certain types of pneumonia.	Explore
179. APTO-253 # 217,515 cells Human approved Clinical trials Targets: MYC KLF4 Mechanism of action: unclear Description: Investigated for cancer, but development discontinued.	Explore
180. Vitamin K4 # 241,419 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated in a clinical trial in Egypt.	Explore
181. Panobinostat # 252,442 cells Human approved Clinical trials Targets: HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 HDAC10 HDAC11 Mechanism of action: HDAC inhibitor (inhibitor/antagonist) Description: Approved for multiple myeloma treatment.	Explore
182. Rimonabant # 295,921 cells Human approved Clinical trials Targets: CNR1 Mechanism of action: unclear Description: Withdrawn due to psychiatric side effects.	Explore
183. Rimonabant (Hydrochloride) # 248,259 cells Human approved Clinical trials Targets: CNR1 Mechanism of action: unclear Description: Withdrawn due to psychiatric side effects, once used as anti-obesity drug.	Explore
184. Ligustrazine # 192,978 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Mainly used in traditional Chinese medicine, limited human trials exist.	Explore
185. Sulfisoxazole # 300,827 cells Human approved Clinical trials Targets: EDNRA EDNRB Mechanism of action: unclear Description: Discontinued in U.S.; previously used for bacterial infections.	Explore
186. Alpelisib # 168,803 cells Human approved Clinical trials Targets: PIK3CA Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: Approved for HR+/HER2- advanced breast cancer in combination with fulvestrant.	Explore
187. Trametinib # 486,077 cells Human approved Clinical trials Targets: MAP2K1 MAP2K2 Mechanism of action: MEK inhibitor (inhibitor/antagonist) Description: Approved for melanoma treatment.	Explore
188. Nevirapine # 202,501 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Antiretroviral for HIV treatment approved for human use.	Explore
189. Tomivosertib # 205,541 cells Human approved Clinical trials Targets: None Mechanism of action: Protein synthesis inhibitor (inhibitor/antagonist) Description: In clinical trials for cancer; not FDA approved for human use yet.	Explore
190. Paclitaxel # 330,148 cells Human approved Clinical trials Targets: None Mechanism of action: Microtubule inhibitor (unclear) Description: Chemotherapy drug approved for cancer treatment.	Explore
191. Docetaxel # 224,057 cells Human approved Clinical trials Targets: None Mechanism of action: Microtubule inhibitor (inhibitor/antagonist) Description: Approved anticancer drug, often used in chemotherapy treatments.	Explore
192. Docetaxel (Trihydrate) # 157,117 cells Human approved Clinical trials Targets: TUBB1 TUBB3 TUBB4B TUBB4A TUBB2A TUBB2B Mechanism of action: Microtubule inhibitor (unclear) Description: Approved cancer treatment, commonly used in chemotherapy.	Explore
193. Roxadustat # 174,468 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for anemia treatment in some countries, e.g., China, Japan.	Explore
194. Thymol # 182,436 cells Human approved Clinical trials Targets: TRPA1 Mechanism of action: unclear Description: Used in clinical trials as antiseptic and antifungal.	Explore
195. Gemfibrozil # 312,814 cells Human approved Clinical trials Targets: PPARA CYP2C9 CYP2C19 CYP2C8 CYP1A2 Mechanism of action: unclear Description: Approved for dyslipidemia treatment.	Explore
196. Vortioxetine # 217,447 cells Human approved Clinical trials Targets: SLC6A4 HTR3A HTR7 Mechanism of action: unclear Description: Approved for major depressive disorder.	Explore
197. OTS514 # 158,710 cells Human approved Clinical trials Targets: MAP3K8 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: Investigational drug in preclinical and early phase clinical trials.	Explore
198. Pralsetinib # 237,989 cells Human approved Clinical trials Targets: RET Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for RET fusion-positive cancers.	Explore
199. Menadione # 117,456 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in trials; a vitamin K analog, not fully approved for human use.	Explore
200. Ciclopirox # 240,717 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for antifungal use, primarily in nail and skin treatments.	Explore
201. Methylthiouracil # 441,501 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in research, not approved for human therapeutic use.	Explore
202. Tolcapone # 344,061 cells Human approved Clinical trials Targets: COMT Mechanism of action: unclear Description: Used in Parkinson's treatment, subject to liver monitoring.	Explore
203. Tolmetin # 248,623 cells Human approved Clinical trials Targets: PTGS1 PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Approved NSAID for pain and inflammation.	Explore
204. Celecoxib # 122,538 cells Human approved Clinical trials Targets: PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Used for arthritis pain and inflammation; approved NSAID.	Explore
205. S-Adenosyl-L-methionine (disulfate tosylate) # 311,356 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used as dietary supplement; approved in some countries for depression treatment.	Explore
206. Lapatinib ditosylate # 232,257 cells Human approved Clinical trials Targets: EGFR ERBB2 Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for use in breast cancer treatment.	Explore
207. LY-2584702 (tosylate salt) # 86,686 cells Human approved Clinical trials Targets: RPS6KB1 Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Investigated in clinical trials for cancer treatment. Not approved for human use.	Explore
208. Edoxaban (tosylate monohydrate) # 290,957 cells Human approved Clinical trials Targets: F10 Mechanism of action: unclear Description: Approved as an anticoagulant for preventing stroke and blood clots.	Explore
209. Lumateperone (tosylate) # 307,654 cells Human approved Clinical trials Targets: HTR2A DRD2 Mechanism of action: unclear Description: Approved for schizophrenia; marketed as Caplyta.	Explore
210. Mozavaptan # 148,482 cells Human approved Clinical trials Targets: AVPR2 Mechanism of action: unclear Description: In trials for conditions like hyponatremia but not approved for use.	Explore
211. Bexarotene # 264,643 cells Human approved Clinical trials Targets: RXRA RXRB RXRG Mechanism of action: Retinoic receptor agonist (activator/agonist) Description: Approved for treating cutaneous T-cell lymphoma.	Explore
212. Sulfatinib # 207,494 cells Human approved Clinical trials Targets: FLT1 KDR FLT4 FGFR1 CSF1R Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Investigated in trials for neuroendocrine tumors, not yet approved for use.	Explore
213. Olanzapine # 280,699 cells Human approved Clinical trials Targets: HTR2A HTR2C DRD2 DRD4 ADRA1A ADRA1B ADRA1D HTR6 CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 Mechanism of action: unclear Description: Olanzapine is used in treatment of schizophrenia and bipolar disorder.	Explore
214. AZD-7648 # 133,462 cells Human approved Clinical trials Targets: PRKDC Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Inhibitor studied for DNA repair, not yet approved for human use.	Explore
215. Megestrol # 263,074 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used for appetite loss and weight gain in cancer/AIDS patients.	Explore
216. Omeprazole (sodium) # 277,106 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved in salt form as acid reflux treatment.	Explore
217. Omeprazole # 334,425 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used as part of racemic mixture for acid-related conditions.	Explore
218. Fedratinib (hydrochloride hydrate) # 254,521 cells Human approved Clinical trials Targets: JAK2 FLT3 RET Mechanism of action: JAK/STAT inhibitor (inhibitor/antagonist) Description: Approved for treatment of myelofibrosis.	Explore
219. Meloxicam # 206,819 cells Human approved Clinical trials Targets: PTGS1 PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Meloxicam is an approved NSAID for pain and inflammation.	Explore
220. Pyridoxine # 218,934 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Vitamin B6; essential nutrient approved for various health conditions.	Explore
221. Pyridoxine (hydrochloride) # 323,820 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Vitamin B6, approved for various medical conditions.	Explore
222. Ornidazole # 293,960 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used for bacterial and protozoal infections, common in some countries.	Explore
223. Raltitrexed # 301,970 cells Human approved Clinical trials Targets: TYMS Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for cancer treatment as thymidylate synthase inhibitor.	Explore
224. BI-3406 # 253,005 cells Human approved Clinical trials Targets: KRAS SOS1 Mechanism of action: RAS inhibitor (inhibitor/antagonist) Description: Investigational compound, clinical trials for KRAS-driven cancers.	Explore
225. Triamcinolone # 244,891 cells Human approved Clinical trials Targets: NR3C1 Mechanism of action: Glucocorticoid receptor agonist (unclear) Description: Approved corticosteroid for various inflammatory and allergic conditions.	Explore
226. Drospirenone # 277,068 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Found in birth control, often combined with ethinyl estradiol.	Explore
227. Eplerenone # 216,397 cells Human approved Clinical trials Targets: NR3C2 Mechanism of action: unclear Description: Used to treat heart failure and hypertension.	Explore
228. Quinestrol # 373,473 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Estrogen approved for use in menopausal therapy and contraceptives.	Explore
229. Estrone sulfate (potassium) # 225,867 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Estrone sulfate used in hormone therapy; potassium salt not specifically approved.	Explore
230. Finasteride # 160,819 cells Human approved Clinical trials Targets: SRD5A2 Mechanism of action: unclear Description: Used for benign prostatic hyperplasia and male pattern baldness.	Explore
231. Fulvestrant # 314,227 cells Human approved Clinical trials Targets: ESR1 Mechanism of action: unclear Description: Estrogen receptor antagonist used for hormone receptor-positive breast cancer.	Explore
232. Monocrotaline # 179,230 cells Human approved Clinical trials Targets: SLC22A1 SLC22A2 Mechanism of action: unclear Description: Toxic pyrrolizidine alkaloid, not approved for human use.	Explore
233. Ouabain (Octahydrate) # 263,412 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated for heart failure but not approved for human use.	Explore
234. Rutin (trihydrate) # 247,151 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Commonly used in supplements; lacks regulatory approval as a drug.	Explore
235. Hesperidin # 179,339 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Studied for various health benefits, but not approved as a drug.	Explore
236. Digitoxin # 157,122 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Clinical trials for certain conditions, but not FDA approved for human use.	Explore
237. Doxorubicin (hydrochloride) # 141,759 cells Human approved Clinical trials Targets: TOP2A TOP2B TOP1 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Commonly used chemotherapy drug for several cancers.	Explore
238. Epirubicin (hydrochloride) # 148,850 cells Human approved Clinical trials Targets: TOP2A Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in chemotherapies as single agent or in combination treatments.	Explore
239. Idarubicin (hydrochloride) # 213,859 cells Human approved Clinical trials Targets: TOP2A Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in acute myeloid leukemia treatment.	Explore
240. Plicamycin # 260,412 cells Human approved Clinical trials Targets: SP1 GSTM2 Mechanism of action: unclear Description: Plicamycin is used to treat testicular cancer and hypercalcemia.	Explore
241. Rifaximin # 195,451 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treatment of IBS and hepatic encephalopathy.	Explore
242. Doxycycline (monohydrate) # 142,724 cells Human approved Clinical trials Targets: MMP7 MMP8 MMP9 MMP13 MMP14 Mechanism of action: unclear Description: Approved antibiotic for bacterial infections.	Explore
243. Fusidic acid # 322,112 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used topically and orally for bacterial infections.	Explore
244. Ipatasertib # 174,297 cells Human approved Clinical trials Targets: AKT1 AKT2 AKT3 Mechanism of action: PI3K/AKT inhibitor (inhibitor/antagonist) Description: Investigational cancer drug, not approved for human use.	Explore
245. Medroxyprogesterone acetate # 237,733 cells Human approved Clinical trials Targets: PGR Mechanism of action: unclear Description: Approved as a contraceptive and for hormone therapy.	Explore
246. Methylprednisolone succinate # 163,101 cells Human approved Clinical trials Targets: NR3C1 Mechanism of action: Glucocorticoid receptor agonist (unclear) Description: Corticosteroid; approved for reducing inflammation in various conditions.	Explore
247. Dexamethasone # 231,379 cells Human approved Clinical trials Targets: NR3C1 Mechanism of action: Glucocorticoid receptor agonist (activator/agonist) Description: Commonly used glucocorticoid for inflammation and immune response regulation.	Explore
248. Dihydroartemisinin # 191,079 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Active metabolite of artemisinin, approved for malaria treatment.	Explore
249. Artesunate # 365,751 cells Human approved Clinical trials Targets: None Mechanism of action: JAK/STAT inhibitor (inhibitor/antagonist) Description: Used for severe malaria, often partnered with other antimalarial drugs.	Explore
250. Artemether # 307,375 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Artemether is used in combination with lumefantrine to treat malaria.	Explore
251. Rapamycin # 239,744 cells Human approved Clinical trials Targets: MTOR FKBP1A Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Approved mainly for organ transplantation and cancer treatment.	Explore
252. Temsirolimus # 251,538 cells Human approved Clinical trials Targets: MTOR Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Approved for treating renal cell carcinoma.	Explore
253. Everolimus # 352,186 cells Human approved Clinical trials Targets: MTOR FKBP1A Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Approved for certain types of cancer, organ transplantation, and tuberous sclerosis.	Explore
254. Tofacitinib # 246,274 cells Human approved Clinical trials Targets: JAK1 JAK2 JAK3 Mechanism of action: JAK/STAT inhibitor (inhibitor/antagonist) Description: Approved for rheumatoid arthritis and other conditions.	Explore
255. Tofacitinib (citrate) # 232,283 cells Human approved Clinical trials Targets: JAK1 JAK2 JAK3 Mechanism of action: JAK/STAT inhibitor (inhibitor/antagonist) Description: Approved for rheumatoid arthritis and other conditions.	Explore
256. Sonidegib # 166,814 cells Human approved Clinical trials Targets: SMO Mechanism of action: Sonic inhibitor (inhibitor/antagonist) Description: Approved for basal cell carcinoma treatment.	Explore
257. AZD-8055 # 237,267 cells Human approved Clinical trials Targets: MTOR Mechanism of action: MTOR inhibitor (inhibitor/antagonist) Description: Investigational drug; explored in trials mainly for cancer treatment.	Explore
258. Elimusertib hydrochloride # 166,019 cells Human approved Clinical trials Targets: ATR Mechanism of action: unclear Description: Tested in trials for cancer but not approved for human use.	Explore
259. Clobetasol propionate # 198,904 cells Human approved Clinical trials Targets: CYP3A5 CYP3A4 Mechanism of action: unclear Description: It's a potent corticosteroid for skin conditions.	Explore
260. Betamethasone dipropionate # 155,944 cells Human approved Clinical trials Targets: NR3C1 Mechanism of action: Glucocorticoid receptor agonist (activator/agonist) Description: A corticosteroid approved and used in topical formulations for inflammation.	Explore
261. Posaconazole # 243,985 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Broad-spectrum antifungal approved for human use.	Explore
262. Pravastatin (sodium) # 525,712 cells Human approved Clinical trials Targets: HMGCR Mechanism of action: unclear Description: Approved as a cholesterol-lowering agent.	Explore
263. Ivermectin # 229,775 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for infections in humans and animals.	Explore
264. Topotecan (hydrochloride) # 453,969 cells Human approved Clinical trials Targets: TOP1 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for treating ovarian, small cell lung, and cervical cancer.	Explore
265. Vinblastine (sulfate) # 233,646 cells Human approved Clinical trials Targets: None Mechanism of action: Microtubule inhibitor (inhibitor/antagonist) Description: Used in cancer treatment, notably Hodgkin's lymphoma.	Explore
266. vincristine # 107,019 cells Human approved Clinical trials Targets: None Mechanism of action: Microtubule inhibitor (inhibitor/antagonist) Description: Used in chemotherapy for various cancers.	Explore
267. Indacaterol (maleate) # 266,965 cells Human approved Clinical trials Targets: ADRB2 Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Approved for COPD as a long-acting bronchodilator.	Explore
268. Pimitespib # 155,110 cells Human approved Clinical trials Targets: HSP90AA1 HSP90AB1 Mechanism of action: unclear Description: Investigated in trials for cancer; not approved for human use yet.	Explore
269. Irinotecan # 226,204 cells Human approved Clinical trials Targets: TOP1 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in cancer treatment, especially for colorectal cancer.	Explore
270. Irinotecan (hydrochloride) # 464,431 cells Human approved Clinical trials Targets: TOP1 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved for cancer treatment as a topoisomerase inhibitor.	Explore
271. Dinaciclib # 45,692 cells Human approved Clinical trials Targets: CDK1 CDK2 CDK5 CDK9 Mechanism of action: CDK inhibitor (inhibitor/antagonist) Description: Investigated in trials; not yet approved for human use.	Explore
272. Pioglitazone # 254,637 cells Human approved Clinical trials Targets: PPARG Mechanism of action: unclear Description: Approved for type 2 diabetes treatment.	Explore
273. Volasertib # 167,796 cells Human approved Clinical trials Targets: PLK1 PLK2 PLK3 Mechanism of action: unclear Description: Investigated for cancer treatment, not approved for human use.	Explore
274. Cyclosporin A # 275,743 cells Human approved Clinical trials Targets: PPP3CA PPP3CB PPP3CC Mechanism of action: unclear Description: Immunosuppressant approved for organ transplant patients.	Explore
275. Erythromycin # 189,544 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Antibiotic used to treat infections; approved for human use.	Explore
276. Azithromycin (hydrate) # 221,754 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved as an antibiotic for bacterial infections.	Explore
277. Perindopril (erbumine) # 387,440 cells Human approved Clinical trials Targets: STAT3 ACE Mechanism of action: unclear Description: Approved ACE inhibitor for hypertension and heart failure.	Explore
278. Sildenafil # 231,405 cells Human approved Clinical trials Targets: PDE5A Mechanism of action: unclear Description: Approved for erectile dysfunction and pulmonary arterial hypertension.	Explore
279. Budesonide # 212,271 cells Human approved Clinical trials Targets: NR3C1 Mechanism of action: Glucocorticoid receptor agonist (activator/agonist) Description: Used for asthma, Crohn's disease, ulcerative colitis.	Explore
280. Hexylresorcinol # 337,432 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in throat lozenges and skin creams for antiseptic purposes.	Explore
281. Oleic acid # 204,032 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in food, cosmetics, and as an excipient in pharmaceuticals.	Explore
282. Fingolimod (hydrochloride) # 228,535 cells Human approved Clinical trials Targets: PAK1 Mechanism of action: unclear Description: Approved for multiple sclerosis treatment.	Explore
283. Daptomycin # 219,241 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved as an antibiotic for skin infections.	Explore
284. Orlistat # 174,892 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used to treat obesity by preventing fat absorption.	Explore
285. Levobupivacaine (hydrochloride) # 205,794 cells Human approved Clinical trials Targets: SCN5A Mechanism of action: unclear Description: Approved as an enantiomer of bupivacaine for anesthetic use.	Explore
286. Proglumide # 208,781 cells Human approved Clinical trials Targets: CCKBR CCKAR Mechanism of action: unclear Description: Proglumide investigated for gastrointestinal use, not widely approved for humans.	Explore
287. Ropivacaine (hydrochloride monohydrate) # 233,544 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: A local anesthetic used in surgeries and pain management.	Explore
288. Macitentan # 199,861 cells Human approved Clinical trials Targets: EDNRA EDNRB Mechanism of action: unclear Description: Approved for pulmonary arterial hypertension treatment.	Explore
289. Vemurafenib # 319,319 cells Human approved Clinical trials Targets: BRAF Mechanism of action: RAF inhibitor (inhibitor/antagonist) Description: Approved for treating BRAF V600E mutation-positive melanoma.	Explore
290. Lidocaine (hydrochloride) # 157,639 cells Human approved Clinical trials Targets: MAP2K1 MAPK1 NFKB1 Mechanism of action: unclear Description: Lidocaine hydrochloride is approved as a local anesthetic.	Explore
291. Sunitinib # 166,667 cells Human approved Clinical trials Targets: KDR PDGFRB Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved anticancer drug used for renal cell carcinoma and gastrointestinal stromal tumors.	Explore
292. Procainamide (hydrochloride) # 147,322 cells Human approved Clinical trials Targets: DNMT1 Mechanism of action: DNA methyltransferase inhibitor (inhibitor/antagonist) Description: Used for arrhythmias; often as its hydrochloride salt form.	Explore
293. Lucanthone # 272,374 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated for cancer treatment, not approved for human use.	Explore
294. RMC-6236 # 274,483 cells Human approved Clinical trials Targets: KRAS Mechanism of action: RAS inhibitor (inhibitor/antagonist) Description: Investigated as a potential cancer treatment, but not approved for human use.	Explore
295. Pemigatinib # 87,862 cells Human approved Clinical trials Targets: FGFR1 FGFR2 FGFR3 FGFR4 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for treating cholangiocarcinoma.	Explore
296. Infigratinib # 215,728 cells Human approved Clinical trials Targets: FGFR1 FGFR2 FGFR3 FGFR4 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Used for bile duct cancer treatment.	Explore
297. NG25 # 145,490 cells Human approved Clinical trials Targets: MAP4K2 MAP3K7 LYN ABL1 ABL2 FER SRC EPHA2 EPHB2 EPHB4 ZAK ZKSCAN1 RAF1 Mechanism of action: Other MAPK inhibitor (inhibitor/antagonist) Description: NG25 is in preclinical stages, not approved for humans.	Explore
298. Abemaciclib # 230,104 cells Human approved Clinical trials Targets: CDK4 CDK6 Mechanism of action: CDK inhibitor (inhibitor/antagonist) Description: FDA approved for HR-positive, HER2-negative breast cancer.	Explore
299. Bimatoprost # 232,275 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treating glaucoma and cosmetic lash applications.	Explore
300. Dorzolamide (hydrochloride) # 192,458 cells Human approved Clinical trials Targets: CA2 Mechanism of action: unclear Description: Approved for glaucoma treatment.	Explore
301. Tazarotene # 235,123 cells Human approved Clinical trials Targets: RARA RARB RARG Mechanism of action: Retinoic receptor agonist (activator/agonist) Description: Topical retinoid approved for psoriasis and acne treatment.	Explore
302. Neratinib # 218,680 cells Human approved Clinical trials Targets: EGFR ERBB2 Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for breast cancer treatment.	Explore
303. Neratinib (maleate) # 305,372 cells Human approved Clinical trials Targets: EGFR ERBB2 Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for HER2-positive breast cancer treatment.	Explore
304. Dapagliflozin # 370,016 cells Human approved Clinical trials Targets: SLC5A2 Mechanism of action: Glucose transporter inhibitor (inhibitor/antagonist) Description: Approved for diabetes treatment.	Explore
305. Auranofin # 192,074 cells Human approved Clinical trials Targets: TXNRD1 TXNRD2 Mechanism of action: unclear Description: Approved for rheumatoid arthritis treatment since 1985.	Explore
306. TAK-901 # 143,892 cells Human approved Clinical trials Targets: AURKB Mechanism of action: unclear Description: Investigational cancer drug; not approved for human use yet.	Explore
307. Loperamide (hydrochloride) # 258,961 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for diarrhea treatment, limited CNS penetration due to P-gp substrate.	Explore
308. Ribociclib # 273,848 cells Human approved Clinical trials Targets: CDK4 CDK6 Mechanism of action: CDK inhibitor (inhibitor/antagonist) Description: Approved for human use in combination with letrozole for breast cancer.	Explore
309. Altretamine # 181,972 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (unclear) Description: Used as a chemotherapy drug for ovarian cancer.	Explore
310. Demeclocycline # 250,986 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used off-label for SIADH, primarily an antibiotic.	Explore
311. Afatinib # 696,323 cells Human approved Clinical trials Targets: EGFR ERBB2 Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for treatment of certain cancers, such as non-small cell lung cancer.	Explore
312. Relugolix # 336,008 cells Human approved Clinical trials Targets: GNRHR Mechanism of action: unclear Description: Approved for prostate cancer and uterine fibroids treatment.	Explore
313. Citalopram (hydrobromide) # 280,687 cells Human approved Clinical trials Targets: SLC6A4 Mechanism of action: unclear Description: Approved antidepressant; selective serotonin reuptake inhibitor (SSRI).	Explore
314. Almonertinib (hydrochloride) # 199,641 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved in China for non-small cell lung cancer.	Explore
315. Almonertinib (mesylate) # 592,031 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved in China for NSCLC treatment.	Explore
316. Diphenhydramine # 261,741 cells Human approved Clinical trials Targets: HRH1 Mechanism of action: unclear Description: Approved antihistamine, used for allergies and as a sleep aid.	Explore
317. ML264 # 213,077 cells Human approved Clinical trials Targets: KLF5 Mechanism of action: unclear Description: No clinical trials found on clinicaltrials.gov.	Explore
318. Methotrexate # 253,217 cells Human approved Clinical trials Targets: DHFR Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Widely used for cancer and autoimmune diseases treatments.	Explore
319. Ivabradine (hydrochloride) # 213,551 cells Human approved Clinical trials Targets: HCN4 Mechanism of action: unclear Description: Approved for human use, primarily for heart failure and angina management.	Explore
320. Rosiglitazone # 196,725 cells Human approved Clinical trials Targets: PPARG TRPC5 TRPM3 Mechanism of action: unclear Description: Approved for diabetes; risk of heart failure in some patients.	Explore
321. Piroxicam # 302,017 cells Human approved Clinical trials Targets: PTGS1 PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Approved NSAID for arthritis and pain relief.	Explore
322. c-Kit-IN-1 # 214,572 cells Human approved Clinical trials Targets: KIT MET KDR PDGFRA PDGFRB Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Experimental compound with no clinical trials reported.	Explore
323. CP21R7 # 136,783 cells Human approved Clinical trials Targets: GSK3B PRKCA Mechanism of action: GSK3 inhibitor (inhibitor/antagonist) Description: Investigational drug in research for neurodegenerative diseases.	Explore
324. 9-ING-41 # 210,225 cells Human approved Clinical trials Targets: GSK3B Mechanism of action: GSK3 inhibitor (inhibitor/antagonist) Description: Investigational drug, not approved for human use yet.	Explore
325. Binimetinib # 548,375 cells Human approved Clinical trials Targets: MAP2K1 MAP2K2 Mechanism of action: MEK inhibitor (inhibitor/antagonist) Description: Investigated for cancer, not approved for human use.	Explore
326. TAK-733 # 146,786 cells Human approved Clinical trials Targets: MAP2K1 Mechanism of action: MEK inhibitor (inhibitor/antagonist) Description: Investigated as anti-cancer MEK inhibitor; not approved for human use.	Explore
327. Bendamustine # 157,509 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (unclear) Description: Approved for use in leukemia and lymphoma treatment.	Explore
328. Benztropine (mesylate) # 259,741 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used for Parkinson's disease and drug-induced extrapyramidal symptoms.	Explore
329. Tadalafil # 211,058 cells Human approved Clinical trials Targets: PDE5A Mechanism of action: unclear Description: Used for erectile dysfunction and pulmonary arterial hypertension.	Explore
330. Vandetanib # 221,797 cells Human approved Clinical trials Targets: EGFR KDR Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for use in medullary thyroid cancer.	Explore
331. Glasdegib # 279,967 cells Human approved Clinical trials Targets: SMO Mechanism of action: Sonic inhibitor (inhibitor/antagonist) Description: Glasdegib is approved for acute myeloid leukemia.	Explore
332. Isocorydine # 256,003 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: No clinical trials found on clinicaltrials.gov	Explore
333. Berbamine # 426,351 cells Human approved Clinical trials Targets: CACNA1C Mechanism of action: unclear Description: Studied for cancer treatment, but not approved for human use yet.	Explore
334. Berbamine (dihydrochloride) # 517,166 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: No clinical trial data found on clinicaltrials.gov.	Explore
335. Cepharanthine # 209,877 cells Human approved Clinical trials Targets: CYP3A4 CYP2E1 CYP2C9 Mechanism of action: unclear Description: Studied for cancer and viral diseases; not approved for human use yet.	Explore
336. Sinomenine # 262,656 cells Human approved Clinical trials Targets: OPRM1 Mechanism of action: unclear Description: Used in trials for pain and arthritis.	Explore
337. LB-100 # 219,882 cells Human approved Clinical trials Targets: PPP2CA PPP2CB Mechanism of action: unclear Description: LB-100 is in clinical trials for cancer treatment.	Explore
338. Entrectinib # 250,201 cells Human approved Clinical trials Targets: NTRK1 NTRK2 NTRK3 ROS1 ALK Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Approved for use in cancers with NTRK gene fusions.	Explore
339. AZD2858 # 94,156 cells Human approved Clinical trials Targets: GSK3B GSK3A Mechanism of action: GSK3 inhibitor (inhibitor/antagonist) Description: Investigated in rodent models.	Explore
340. Capmatinib # 185,971 cells Human approved Clinical trials Targets: MET Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for NSCLC treatment by FDA in May 2020.	Explore
341. Apalutamide # 213,510 cells Human approved Clinical trials Targets: AR Mechanism of action: Androgen receptor antagonist (inhibitor/antagonist) Description: Used for non-metastatic castration-resistant prostate cancer.	Explore
342. Regorafenib # 479,625 cells Human approved Clinical trials Targets: BRAF FLT1 FLT4 KDR KIT PDGFRB RAF1 RET TEK Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Used for metastatic colorectal cancer, GIST, HCC.	Explore
343. Phenylephrine (hydrochloride) # 269,366 cells Human approved Clinical trials Targets: ADRA1A ADRA1B ADRA1D Mechanism of action: Adrenoceptor agonist (activator/agonist) Description: Widely used as a decongestant and in eye drops.	Explore
344. Rucaparib (phosphate) # 293,357 cells Human approved Clinical trials Targets: PARP1 PARP2 PARP3 Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Approved as a cancer therapy PARP inhibitor.	Explore
345. Clopidogrel # 314,754 cells Human approved Clinical trials Targets: P2RY12 Mechanism of action: unclear Description: Antiplatelet drug approved for preventing stroke, heart attack in high-risk patients.	Explore
346. Dimethyl fumarate # 288,592 cells Human approved Clinical trials Targets: NFE2L2 Mechanism of action: unclear Description: Approved for multiple sclerosis treatment.	Explore
347. Methyl aminolevulinate (hydrochloride) # 308,069 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in photodynamic therapy for actinic keratosis.	Explore
348. Mebendazole # 251,188 cells Human approved Clinical trials Targets: TUBA1A TUBA1B TUBA1C TUBB TUBB1 TUBB2A TUBB3 TUBB4A TUBB4B TUBB6 Mechanism of action: Microtubule inhibitor (inhibitor/antagonist) Description: Approved for treating parasitic worm infestations.	Explore
349. Tranilast # 213,758 cells Human approved Clinical trials Targets: PLA2G2A EGR1 Mechanism of action: unclear Description: Approved for asthma and allergic disorders in some countries.	Explore
350. Gefitinib # 375,118 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for non-small cell lung cancer.	Explore
351. Simotinib # 126,219 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Investigated in trials, but not approved for human use.	Explore
352. Bergenin # 284,145 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated for anti-inflammatory and antiulcer effects in clinical trials.	Explore
353. Ferulic acid # 137,408 cells Human approved Clinical trials Targets: FGFR1 FGFR2 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Used in skincare; not an FDA-approved drug.	Explore
354. Amsacrine # 272,619 cells Human approved Clinical trials Targets: TOP2A Mechanism of action: DNA synthesis/repair inhibitor (inhibitor/antagonist) Description: Used in the treatment of acute leukemias.	Explore
355. Palmatine (chloride) # 262,155 cells Human approved Clinical trials Targets: IDO1 WNV NS2B-NS3 Mechanism of action: unclear Description: Used in some traditional medicine; lacks formal approval for human use.	Explore
356. Berberine (chloride hydrate) # 338,273 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in trials for metabolic/heart diseases, not FDA-approved.	Explore
357. Futibatinib # 182,881 cells Human approved Clinical trials Targets: FGFR1 FGFR2 FGFR3 FGFR4 Mechanism of action: Other TK inhibitor (inhibitor/antagonist) Description: Used for cholangiocarcinoma; FDA approved.	Explore
358. Tubulin inhibitor 6 # 213,872 cells Human approved Clinical trials Targets: None Mechanism of action: Microtubule inhibitor (inhibitor/antagonist) Description: No available data on human use or clinical trials.	Explore
359. Anethole trithione # 318,727 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Investigated for dry mouth in clinical trials.	Explore
360. Cabozantinib (S-malate) # 227,189 cells Human approved Clinical trials Targets: MET KDR AXL Mechanism of action: Multi-TK inhibitor (inhibitor/antagonist) Description: Approved for medullary thyroid cancer and renal cell carcinoma.	Explore
361. Fluvoxamine # 190,663 cells Human approved Clinical trials Targets: SLC6A4 Mechanism of action: unclear Description: SSRI approved for treating OCD and depression.	Explore
362. Fluvoxamine (maleate) # 229,856 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved for treating OCD and depression-related disorders in humans.	Explore
363. Erlotinib # 249,565 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for human use for non-small cell lung cancer.	Explore
364. Belzutifan # 93,147 cells Human approved Clinical trials Targets: EPAS1 Mechanism of action: unclear Description: Approved for treating certain cancer types.	Explore
365. Vismodegib # 178,999 cells Human approved Clinical trials Targets: SMO ABCB1 ABCG2 Mechanism of action: Sonic inhibitor (inhibitor/antagonist) Description: Approved for treating basal cell carcinoma.	Explore
366. Nimesulide # 174,956 cells Human approved Clinical trials Targets: PTGS2 Mechanism of action: Cyclooxygenase inhibitor (inhibitor/antagonist) Description: Withdrawn in some countries due to safety concerns; not FDA-approved.	Explore
367. Nafamostat (mesylate) # 242,220 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Approved in some countries, often used as anticoagulant.	Explore
368. Busulfan # 244,932 cells Human approved Clinical trials Targets: None Mechanism of action: DNA synthesis/repair inhibitor (unclear) Description: Approved for use in bone marrow transplantation.	Explore
369. 18β-Glycyrrhetinic acid # 199,550 cells Human approved Clinical trials Targets: None Mechanism of action: unclear Description: Used in cosmetics, derived from licorice root, no approval for human drugs.	Explore
370. Trametinib (DMSO_TF solvate) # 260,038 cells Human approved Clinical trials Targets: MAP2K1 MAP2K2 Mechanism of action: MEK inhibitor (inhibitor/antagonist) Description: Approved for use in cancer treatment (e.g., melanoma).	Explore
371. Sacubitril/Valsartan # 247,200 cells Human approved Clinical trials Targets: AGTR1 Mechanism of action: unclear Description: Combination drug known as Entresto, used for heart failure treatment.	Explore
372. Pitavastatin (Calcium) # 102,552 cells Human approved Clinical trials Targets: HMGCR Mechanism of action: unclear Description: Approved for lowering cholesterol, part of statins class of drugs.	Explore
373. Verteporfin # 158,791 cells Human approved Clinical trials Targets: YAP1 Mechanism of action: unclear Description: Used in photodynamic therapy for macular degeneration.	Explore
374. Quinidine (15% dihydroquinidine) # 225,274 cells Human approved Clinical trials Targets: KCNH2 Mechanism of action: unclear Description: Approved for arrhythmias as part of quinine alkaloids.	Explore
375. Canagliflozin (hemihydrate) # 310,049 cells Human approved Clinical trials Targets: SLC5A2 Mechanism of action: Glucose transporter inhibitor (inhibitor/antagonist) Description: Approved for type 2 diabetes.	Explore
376. Osimertinib (mesylate) # 217,286 cells Human approved Clinical trials Targets: EGFR Mechanism of action: EGFR/ERBB inhibitor (inhibitor/antagonist) Description: Approved for non-small cell lung cancer treatment.	Explore
377. γ-Oryzanol # 261,962 cells Human approved Clinical trials Targets: None Mechanism of action: DNA methyltransferase inhibitor (inhibitor/antagonist) Description: Used in supplements; limited human data.	Explore